Myeloproliferative neoplasms and acute myeloid leukemia
New insights into the use of decitabine versus hydroxyurea in the treatment of advanced proliferative chronic myelomonocytic leukemia.
● Prof. Dr. med. habil. Uwe Platzbecker
Type 2 diabetes
New insights into the impact of the direct factor Xa inhibitor rivaroxaban on endothelial function in patients with type 2 diabetes and high cardiovascular risk.
● Prof. Dr. med. habil. Stefan Bornstein
New insights into the impact of smoking history, DLCO, chest CT findings, and left heart disease risk factors on the classification of unexplained precapillary pulmonary hypertension (IPAH).
● Prof. Dr. med. habil. David Pittrow
Superficial vein thrombosis–treatment and complications
New Evidence on the Role of the Oral Factor Xa Inhibitor Rivaroxaban in the Treatment of Patients with Symptomatic Superficial Venous Thrombosis
● Prof. Dr. med. habil. Jan Beyer-Westendorf
New insights into the use of Sudoscan technology compared with quantitative sudomotor axon reflex testing (QSART) in the detection of diabetic polyneuropathy (DPN).
● Prof. Dr. med. habil. Tjalf Ziemssen
VEGF and Type 2 diabetes
New insights into intra-individual variability and circadian rhythm of vascular endothelial growth factors (VEGF) in patients with type 2 diabetes.
● Prof. Dr. med. habil. Katrin Engelmann
Idiopathic pulmonary fibrosis
New insights into the impact of antifibrotic therapy on survival and the course of disease in patients with idiopathic pulmonary fibrosis (IPF)
● Prof. Dr. med. habil. Dirk Koschel
Hit enter to search or ESC to close
You are using an outdated browser. The website may not be displayed correctly. Close